Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced a new partnership with the Baylor Research Institute, operating as Baylor Scott & White Research Institute in Dallas, Texas. This collaboration marks a significant development in Estrella's ongoing STARLIGHT-1 Phase I/II clinical trial, which is focused on evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). The partnership aims to expand the clinical footprint, accelerating the development of EB103 and enhancing patient access to this promising therapy. The Baylor Research Institute will serve as a new clinical site, now open for patient enrollment, furthering Estrella's mission to deliver safer and more effective treatments for NHL patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.